United States: FDA Draft Guidance Clarifies Criteria And Process for Obtaining Rare Pediatric Disease Priority Review Vouchers

On November 17, 2014, the Food and Drug Administration ("FDA") released a draft guidance entitled Rare Pediatric Disease Priority Review Vouchers, which describes an incentive program for the development of drugs intended to treat rare pediatric diseases. Congress established this program more than two years ago when it enacted the Food and Drug Administration Safety and Innovation Act, adding section 529 to the Federal Food, Drug, and Cosmetic Act. Section 529 provides that the sponsor of a "rare pediatric disease product application," upon approval of such application, is eligible for a voucher that can be used to obtain priority review for a subsequent new drug application ("NDA") or biologics license application ("BLA"). Priority review means that an application has an FDA review clock of six months, rather than the standard review clock of ten months.1

FDA's draft guidance clarifies key statutory definitions, explains the processes by which sponsors can request a rare pediatric disease designation and a rare pediatric disease priority review voucher, and elaborates on other aspects of the program, including the transferability of vouchers and the relationship between rare pediatric disease designation and orphan drug designation.

Definition of a Rare Pediatric Disease Product Application

Under section 529(a)(4), a rare pediatric disease product application is defined as a human drug application (i.e., an NDA or BLA, with limited exceptions) that meets the following criteria:

  • Is for the prevention or treatment of a "rare pediatric disease," meaning a disease that satisfies the definition of "rare disease or condition" under the Orphan Drug Act and that primarily affects individuals from 0-18 years old;
  • Is for a drug that contains no active ingredient (including any ester or salt of the active ingredient) previously approved in another application;
  • Is deemed by FDA as eligible for priority review;
  • Is not an abbreviated new drug application or biosimilar application;
  • Relies on clinical data derived from pediatric studies and dosages of the drug intended for the pediatric population;
  • Does not seek approval for an adult indication in the original rare pediatric disease product application; and 
  • Is approved after July 9, 2012.

FDA's draft guidance clarifies key aspects of these criteria. FDA interprets the definition of "rare pediatric disease" to require that greater than 50% of the affected population in the U.S. be aged 0 through 18 years. Additionally, with regard to the criterion that the original application not seek approval for an adult indication, FDA's draft guidance states that, to preserve voucher eligibility, the applicant cannot seek approval for a different adult indication (i.e., for a different disease/condition) in the original rare pediatric disease application. If the applicant is seeking approval in both pediatric and adult populations for the same rare pediatric disease, the applicant is still eligible for a voucher. FDA explains that it is adopting this liberal interpretation to avoid incentivizing sponsors to exclude adults from clinical trials for rare pediatric diseases or to exclude adult data from original applications.

Designation Request and Voucher Request Processes

The draft guidance also outlines procedures for requesting rare pediatric disease designation and rare pediatric disease priority review vouchers, including the information to include in such requests. Under section 529, any request for rare pediatric disease designation must be submitted at the same time as a request for orphan drug designation or fast track designation. The draft guidance provides that FDA will accept designation requests submitted at other times, so long as they are received before FDA has filed the original marketing application for the drug. 

FDA emphasizes that the rare pediatric disease designation process is entirely voluntary. Even if a sponsor does not request designation, the sponsor may still request, and is still eligible for, a voucher when submitting the original marketing application. Additionally, although voucher requests by sponsors are not technically required under section 529, FDA notes that the submission of such requests will ensure that FDA has all the necessary information to evaluate voucher eligibility.

Recent Developments Under the Existing Program

Although relatively new, the rare pediatric disease priority review voucher program may prove to be a powerful incentive. In February 2014, FDA awarded the first rare pediatric disease priority review voucher to BioMarin Pharmaceutical Inc. when the company received approval for Vimizim (elosulfase alfa), an enzyme replacement therapy to treat the metabolism disease Morquio A syndrome. Even though FDA's approval of Vimizim covered both pediatric and adult use for Morquio A syndrome, FDA determined BioMarin's application was eligible for a priority review voucher, consistent with the liberal interpretation of section 529 adopted by the draft guidance. In July 2014, Biomarin announced that it had sold the voucher to Regeneron Ireland for $67.5 million.

Ropes & Gray will continue to monitor developments in this area. If you have any questions, please contact any member of Ropes & Gray's FDA regulatory practice or your usual Ropes & Gray Advisor.

1 Under FDA's commitments as part of the Prescription Drug User Fee Act V, the FDA review clock begins at the end of a 60-day filing review period following the original submission of an application.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions